share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

福泰制药 | 4:持股变动声明-高管 Kewalramani Reshma
美股sec公告 ·  08/01 16:23
Moomoo AI 已提取核心信息
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a sale of 15,202 shares of common stock on July 30, 2024. The transaction was executed at a price of $505.00 per share, resulting in a total market value of $7,677,010. Following the sale, Reshma's direct holdings in the company amount to 90,970 shares. The sale took place through an open market or private sale, as indicated by the transaction code 'S'.
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a sale of 15,202 shares of common stock on July 30, 2024. The transaction was executed at a price of $505.00 per share, resulting in a total market value of $7,677,010. Following the sale, Reshma's direct holdings in the company amount to 90,970 shares. The sale took place through an open market or private sale, as indicated by the transaction code 'S'.
福泰制药首席执行官兼总裁Kewalramani Reshma于2024年7月30日完成了15202股普通股的出售。该交易价格为每股505.00美元,总市值为7,677,010美元。出售后,Reshma在公司内的直接持股数量为90,970股。该销售通过公开市场或私人交易进行,由交易代码“S”表示。
福泰制药首席执行官兼总裁Kewalramani Reshma于2024年7月30日完成了15202股普通股的出售。该交易价格为每股505.00美元,总市值为7,677,010美元。出售后,Reshma在公司内的直接持股数量为90,970股。该销售通过公开市场或私人交易进行,由交易代码“S”表示。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息